Nifty
:
23151.10
Sensex
:
74563.92
-488.05 (-2.06%)
-1470.50 (-1.93%)
Nifty
Sensex
:
:
23151.10
74563.92
-488.05 (-2.06%)
-1470.50 (-1.93%)

Shilpa Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
56/99

BSE: 530549 | NSE: SHILPAMED

NSE BSE
312.80
13-Mar-2026
  • Open
  • High
  • Low
  • Previous Close
  •  334
  •  335.6
  •  312
  •  332.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  367996
  •  117216347.7
  •  500
  •  259.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,125.62
  • 40.83
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,694.91
  • 0.16%
  • 2.46

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 40.13%
  • 9.08%
  • 27.80%
  • FII
  • DII
  • Others
  • 10.97%
  • 6.99%
  • 5.03%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.03
  • 7.38
  • 7.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.63
  • 12.10
  • 28.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -3.20
  • -11.93
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.70
  • 72.39
  • 69.86

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.49
  • 2.41
  • 2.52

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.12
  • 23.83
  • 24.01

Earnings Forecasts:

(Updated: 14-03-2026)
Description
2024
2025
2026
2027
Adj EPS
4
P/E Ratio
78.20
Revenue
1286.41
1468.4
1705.4
1897.8
EBITDA
317.05
475.4
601.1
653
Net Income
78.29
218
307.4
340.1
ROA
2.45
P/B Ratio
2.58
2.37
2.12
1.89
ROE
3.75
8
11
11
FCFF
-180.13
FCFF Yield
-2.53
Net Debt
561.78
BVPS
121.29
132.2
147.8
165.2

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
409.73
319.30
28.32%
369.97
343.80
7.61%
321.46
292.51
9.90%
330.81
291.69
13.41%
Expenses
295.43
238.66
23.79%
261.69
257.79
1.51%
229.82
218.99
4.95%
254.04
221.63
14.62%
EBITDA
114.30
80.65
41.72%
108.28
86.00
25.91%
91.64
73.52
24.65%
76.77
70.06
9.58%
EBIDTM
27.90%
25.26%
29.27%
25.02%
28.51%
25.13%
23.21%
24.02%
Other Income
0.81
1.18
-31.36%
1.75
4.99
-64.93%
6.38
9.52
-32.98%
7.57
2.49
204.02%
Interest
10.68
11.75
-9.11%
15.67
25.55
-38.67%
18.78
23.74
-20.89%
14.49
24.20
-40.12%
Depreciation
30.36
28.81
5.38%
29.82
28.28
5.45%
28.92
27.11
6.68%
28.79
26.63
8.11%
PBT
61.21
41.27
48.32%
64.54
37.16
73.68%
50.31
32.20
56.24%
12.97
27.85
-53.43%
Tax
16.27
9.83
65.51%
20.36
18.83
8.13%
2.69
14.62
-81.60%
0.77
3.21
-76.01%
PAT
44.94
31.44
42.94%
44.18
18.33
141.03%
47.62
17.58
170.88%
12.21
24.64
-50.45%
PATM
10.97%
9.85%
11.94%
5.33%
14.81%
6.01%
3.69%
8.45%
EPS
2.28
1.63
39.88%
2.25
0.92
144.57%
2.40
0.72
233.33%
0.74
1.41
-47.52%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
1,431.97
1,286.41
1,151.60
1,050.11
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
Net Sales Growth
14.81%
11.71%
9.66%
-8.33%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
 
Cost Of Goods Sold
422.91
397.67
394.23
416.04
383.22
270.73
277.73
257.03
355.87
371.81
366.19
Gross Profit
1,009.06
888.74
757.37
634.07
762.30
630.40
630.18
476.36
432.95
407.36
350.25
GP Margin
70.47%
69.09%
65.77%
60.38%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
Total Expenditure
1,040.98
982.48
916.10
961.84
948.32
729.43
693.40
579.39
637.60
617.55
556.44
Power & Fuel Cost
-
53.74
52.41
56.79
52.43
40.25
38.76
33.57
28.86
26.30
21.90
% Of Sales
-
4.18%
4.55%
5.41%
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
Employee Cost
-
292.71
281.39
286.39
264.49
235.31
196.59
176.40
149.35
127.87
90.09
% Of Sales
-
22.75%
24.43%
27.27%
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
Manufacturing Exp.
-
122.29
95.70
110.32
120.03
89.12
79.19
61.23
59.96
52.55
45.35
% Of Sales
-
9.51%
8.31%
10.51%
10.48%
9.89%
8.72%
8.35%
7.60%
6.74%
6.33%
General & Admin Exp.
-
59.02
43.99
46.86
71.58
47.71
70.26
27.20
22.50
16.95
14.11
% Of Sales
-
4.59%
3.82%
4.46%
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
Selling & Distn. Exp.
-
26.53
21.42
18.56
29.36
20.79
10.40
6.72
6.37
4.75
7.27
% Of Sales
-
2.06%
1.86%
1.77%
2.56%
2.31%
1.15%
0.92%
0.81%
0.61%
1.01%
Miscellaneous Exp.
-
30.52
26.96
26.89
27.22
25.51
20.48
17.23
14.68
17.32
7.27
% Of Sales
-
2.37%
2.34%
2.56%
2.38%
2.83%
2.26%
2.35%
1.86%
2.22%
1.61%
EBITDA
390.99
303.93
235.50
88.27
197.20
171.70
214.51
154.00
151.23
161.61
159.99
EBITDA Margin
27.30%
23.63%
20.45%
8.41%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
Other Income
16.51
36.27
17.16
31.41
20.90
40.09
22.23
15.56
32.62
29.34
11.36
Interest
59.62
75.53
91.80
58.65
41.17
21.87
4.56
3.68
2.66
3.13
3.93
Depreciation
117.89
112.99
107.87
95.50
79.80
53.98
43.78
42.06
37.22
30.64
23.14
PBT
189.03
151.68
52.99
-34.47
97.13
135.95
188.40
123.82
143.96
157.17
144.28
Tax
40.09
44.04
22.39
-7.36
41.68
48.85
33.49
26.18
33.91
42.04
35.62
Tax Rate
21.21%
35.63%
37.87%
21.35%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
PAT
148.95
78.30
31.88
-32.48
60.66
147.78
156.15
112.26
105.24
107.57
108.34
PAT before Minority Interest
148.95
78.30
31.96
-30.92
60.58
146.20
154.56
109.50
102.86
104.45
104.74
Minority Interest
0.00
0.00
-0.08
-1.56
0.08
1.58
1.59
2.76
2.38
3.12
3.60
PAT Margin
10.40%
6.09%
2.77%
-3.09%
5.30%
16.40%
17.20%
15.31%
13.34%
13.81%
15.12%
PAT Growth
61.92%
145.61%
-
-
-58.95%
-5.36%
39.10%
6.67%
-2.17%
-0.71%
 
EPS
7.62
4.00
1.63
-1.66
3.10
7.56
7.98
5.74
5.38
5.50
5.54

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,372.24
1,808.69
1,783.28
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
Share Capital
9.78
8.68
8.68
8.68
8.15
8.15
8.15
8.15
8.01
7.71
Total Reserves
2,362.46
1,800.01
1,774.60
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
Non-Current Liabilities
259.81
589.44
345.12
452.82
561.37
256.94
166.62
153.48
251.26
67.23
Secured Loans
231.96
560.16
242.92
353.49
473.87
164.48
80.39
67.09
141.20
0.03
Unsecured Loans
0.00
0.00
45.90
0.11
0.35
0.53
0.70
1.03
1.30
0.00
Long Term Provisions
25.54
22.43
17.65
19.08
15.48
26.17
21.77
20.32
16.89
13.96
Current Liabilities
674.23
693.59
784.45
611.54
587.46
410.82
253.44
265.84
236.90
222.07
Trade Payables
95.38
174.15
142.80
146.04
76.54
92.55
80.72
103.74
111.86
106.48
Other Current Liabilities
222.13
138.05
276.56
240.13
254.21
142.10
81.62
59.59
28.03
36.49
Short Term Borrowings
306.81
360.73
344.17
202.90
243.40
165.27
86.58
98.12
92.41
74.10
Short Term Provisions
49.91
20.66
20.92
22.46
13.31
10.89
4.52
4.39
4.60
5.00
Total Liabilities
3,297.74
3,082.98
2,903.93
2,875.50
2,616.33
1,989.21
1,610.02
1,499.13
1,472.22
930.89
Net Block
1,417.84
1,384.86
1,368.33
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
Gross Block
2,075.99
1,946.75
1,846.68
1,727.09
1,421.10
986.42
853.16
793.24
704.89
582.20
Accumulated Depreciation
658.15
561.89
478.35
385.25
310.57
335.98
295.15
259.04
212.96
188.79
Non Current Assets
2,312.07
2,206.74
2,134.37
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
Capital Work in Progress
821.77
718.78
655.33
506.18
541.29
666.25
429.12
209.85
140.51
91.90
Non Current Investment
34.54
39.91
42.66
34.23
21.22
10.45
2.25
20.79
27.99
34.15
Long Term Loans & Adv.
36.55
53.32
56.53
93.90
43.10
32.42
48.75
37.47
77.09
52.39
Other Non Current Assets
1.37
9.87
11.52
12.15
13.46
5.78
26.84
24.86
4.80
4.83
Current Assets
985.67
876.24
769.55
887.19
862.47
623.85
545.06
671.97
729.88
354.21
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
119.54
224.62
59.63
Inventories
347.93
344.93
319.82
355.24
333.19
226.43
187.67
188.71
190.00
134.23
Sundry Debtors
440.84
392.05
324.35
386.33
233.54
246.79
203.73
220.27
170.93
125.43
Cash & Bank
28.52
31.77
21.56
34.11
123.60
44.56
94.54
73.83
100.39
11.03
Other Current Assets
168.38
16.28
15.53
9.36
172.14
106.06
59.13
69.62
43.94
23.90
Short Term Loans & Adv.
150.79
91.22
88.29
102.16
146.24
95.97
47.99
56.59
31.61
21.18
Net Current Assets
311.44
182.65
-14.89
275.66
275.01
213.04
291.62
406.13
492.98
132.14
Total Assets
3,297.74
3,082.98
2,903.92
2,875.49
2,592.07
1,989.20
1,610.02
1,499.13
1,472.21
930.89

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
132.18
136.67
179.92
105.13
46.93
124.38
146.78
44.92
37.48
128.70
PBT
122.33
54.34
-38.28
102.26
196.79
188.40
143.70
136.77
146.49
140.36
Adjustment
195.04
221.44
147.81
109.34
4.03
41.32
20.44
18.83
17.19
20.61
Changes in Working Capital
-138.18
-97.92
102.77
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
Cash after chg. in Working capital
179.20
177.86
212.30
139.62
94.53
166.57
182.85
85.94
71.08
158.27
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-47.02
-41.19
-32.37
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-199.08
-166.58
-232.61
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
Net Fixed Assets
-78.45
-17.18
-22.18
384.16
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
Net Investments
-1,033.05
-2.53
-6.42
-18.18
-117.95
-4.44
133.96
95.51
-172.72
-14.09
Others
912.42
-146.87
-204.01
-651.48
-14.31
-280.80
-73.16
32.48
82.72
-2.97
Cash from Financing Activity
62.65
46.77
45.80
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
Net Cash Inflow / Outflow
-4.25
16.86
-6.89
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
Opening Cash & Equivalents
31.76
19.07
25.62
122.85
44.31
34.13
73.83
99.97
7.05
3.61
Closing Cash & Equivalent
28.52
31.76
19.07
25.34
123.34
44.31
34.36
73.83
99.97
6.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
121.29
104.19
205.44
209.93
181.37
163.06
146.89
133.09
123.17
82.91
ROA
2.45%
1.07%
-1.07%
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
ROE
3.75%
1.78%
-1.71%
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
ROCE
6.94%
5.49%
0.80%
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
Fixed Asset Turnover
0.64
0.61
0.59
0.73
0.75
0.99
0.89
1.06
1.22
1.36
Receivable days
118.16
113.53
123.51
98.75
94.03
90.56
105.51
90.20
69.00
52.26
Inventory Days
98.29
105.35
117.32
109.68
110.03
83.24
93.66
87.32
75.49
66.97
Payable days
123.69
146.72
126.70
106.00
107.72
47.69
58.00
61.51
60.89
60.10
Cash Conversion Cycle
92.76
72.15
114.12
102.43
96.33
126.11
141.17
116.00
83.61
59.13
Total Debt/Equity
0.25
0.52
0.45
0.37
0.57
0.29
0.16
0.18
0.24
0.14
Interest Cover
2.62
1.59
0.35
3.48
9.92
42.34
40.09
55.10
49.69
37.07

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Shilpa Medicare’s arm, SteinCares enter into strategic licensing agreement
    24th Feb 2026, 11:20 AM

    Under the agreement, SteinCares will hold exclusive rights to register, commercialize, and distribute the biosimilar across the region

    Read More
  • Shilpa Medicare enters into strategic partnership with NXI Therapeutics AG
    13th Feb 2026, 12:21 PM

    The collaboration spans early development through commercialization, positioning Shilpa as a lifecycle partner for the program

    Read More
  • Shilpa Medicare - Quarterly Results
    7th Feb 2026, 00:00 AM

    Read More
  • Shilpa Medicare’s arm gets Orphan Drug Designation from USFDA
    28th Jan 2026, 16:44 PM

    The designation provides meaningful regulatory and commercial incentives, including development support, tax credits, and market exclusivity upon approval

    Read More
  • Shilpa Medicare gets initial authorization for Rotigotine Transdermal Patch from Europe
    12th Dec 2025, 12:05 PM

    Shilpa’s Rotigotine patches are indicated for treatment of Restless Legs Syndrome and Parkinson’s disease

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.